Xcout Intel
Attralus, Inc.
Attralus, Inc. is a biopharmaceutical company headquartered in Naples, Florida, focused on creating transformative medicines and novel pan-amyloid removal therapeutics and diagnostics.
Subscribe to see Attralus, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Attralus, Inc. at a glance
Attralus, Inc. is a biotechnology company headquartered in United States. It has raised at least $197.6M across the 3 funding rounds on record. Its most recent funding round raised $56M in January 2024. Xcout tracks 15 named people at Attralus, Inc., including Mark Timney (CHIEF EXECUTIVE OFFICER).
Attralus, Inc. leadership
- Mark TimneyCHIEF EXECUTIVE OFFICER
- Glen FirestoneCHIEF BUSINESS OFFICER
- Gregory BellCHIEF MEDICAL OFFICER
- Jonathan WallCO-FOUNDER & INTERIM CHIEF SCIENTIFIC OFFICER
- Karen RobertsonVICE PRESIDENT, REGULATORY AFFAIRS
- Nicolas Angell, PhDVICE PRESIDENT, CMC
9 more named people on record for Attralus, Inc., with roles, board committees and tenure — see the full roster →
Attralus, Inc. funding rounds
At least $197.6M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $56M | 9 named | |
| Series B | $116.6M | 8 named | |
| Series A | $25M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Attralus, Inc. competitors
A few of Attralus, Inc.'s closest competitors — see the full list of competitors and alternatives →
Attune Biotech Inc. is a biopharmaceutical company that develops novel medicines to treat underserved disorders, focusing on neuroimmune, inflammatory, infectious disease, and metabolic applications. The company utilizes a proprietary platform approach featuring its flagship candidate, Lodonal, which is engineered with pharmaceutical-grade consistency and precision dosing to restore immune balance.
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Autobahn Therapeutics, Inc. is a privately held biopharmaceutical company with its corporate office and headquarters located in San Diego, California, focused on restoring hope for patients.
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company located in Mission Viejo, California, focused on developing a platform of compounds for biodefense and fibrosis applications.
Sironax is a biopharmaceutical company committed to developing new treatments by targeting underlying contributors of degeneration, including neurodegenerative, inflammatory, and metabolic disorders.
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
Get Attralus, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Attralus, Inc. in Xcout Intel
- 15 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access